The future of life insurance starts here
GRAIL's Life Insurance Advisory Committee is committed to raising awareness of the benefits of multi-cancer early detection testing. This innovative group of industry leaders has an important goal: Help one million life insurance policyholders screen for some of the deadliest cancers with the Galleri test.
Meet our Life Insurance Advisory Committee members
These forward-thinking industry leaders are embracing innovative solutions that go beyond traditional coverage.
Jim Duff
Committee Chairman, Thought Leader
Jim has over 35 years of experience in the insurance industry-leading brokerage sales team. He handles the sales teams supporting life, long-term care, accidental death, critical advantage, disability and annuities, and business distribution. His leadership roles include Tellus Brokerage Connections (a Crump company); Crump Solution Centers, where he built one of the industry’s top-producing distribution organizations, and Transamerica Life Insurance Company. LinkedIn
Diana Greenberg
Partner at Simplicity
In addition to her role at Simplicity, Diana is the president and CEO of Total Financial (a Simplicity company), the family business started by her parents in 1985. Under her leadership, the company has improved processes and adopted technology to better compete within the changing industry landscape. Diana serves as a board member at the National Association of Independent Life Brokerage Agencies. She was featured as one of the Top 20 Pioneering and Innovative CEOs by MYTECHMAG and Success Pitchers Magazine. LinkedIn
Dan Labert
President, Independent Distribution at Finesca
Dan is a strategic association executive with diverse industry experience. He joined Finesca in 2022 and also has extensive leadership experience with organizations including the National Association of Independent Life Brokerage Agencies, the National Association of Consumer Bankruptcy Attorneys, the Pennsylvania Institute of Certified Public Accountants, The Leadership Institute, the Bar Association of Lehigh County, United States Lacrosse, and Public Broadcasting Service (WLVT). He is known for building lean, top-performing teams; elevating an organization’s image; and delivering rapid, record-setting revenue gains. Dan is also a professional speaker and published writer. LinkedIn
Bill Shelow
President and CEO at Libra Insurance Partners
Bill is a sought-after speaker, author, and thought leader within the financial industry. At LIBRA Insurance Partners, the country's largest independently owned insurance marketing organization, he is known for his passion, insights, and innovation in closing gaps between carriers, agencies, agents, and consumers in life insurance distribution. He’s also served as president of Duncan Financial Group, CEO of Wealth Preservation and Management t/a Atlantic Financial Group, and enjoyed 25 years with Harleysville Insurance Companies. LinkedIn
Jason Grover
President at Ash Brokerage
As president of Ash Brokerage, Jason focuses on creating best-in-class platforms to increase awareness of insurance solutions through partnerships with insurance carriers, financial institutions, and individual advisors. He is also a member of the executive leadership team and the company’s board of directors. Jason joined Ash in 2001 to lead national account development and create its first Culture Center. Before that, Jason built a successful practice as a financial representative with a mutual insurance company in New York City. Jason serves on the board of Techficient, Humane Fort Wayne, and NAILBA, a leading insurance advocacy group. LinkedIn
Marc Verbos
EVP | President, Distribution at AIMCOR Group
With more than 20 years of experience, Marc has held various leadership and distribution roles. He joined AIMCOR in 2014 as the vice president of business development and led the launch of its institutional business, AIMCOR EIG. In 2019, Marc moved into a senior leadership role as AIMCOR’s executive vice president and was appointed the president of Aligned Distribution in 2022, leading ICON (a joint venture with AmeriLife), AIMCOR EIG, and Tick!. He serves on various industry committees and resides on two carrier advisory boards, the AmeriLife Wealth Division Board of Directors, the Life Operations Management Roundtable (OMB), and as a principal advisor for two technology vendors. LinkedIn
Michael Babikian
CEO at First Financial Resources
Michael is an established innovator and seasoned management executive. He joined First Financial Resources in 2020 as its chief operating officer and now serves as its CEO. He founded LegacyShield, where he successfully combined legacy planning with tech solutions, and served as president and CEO of Transamerica Brokerage. LinkedIn
Marc Schwartz
Managing Principal at NFP Windsor
With more than 30 years of experience in leadership at NFP and Windsor Insurance, Marc currently serves as managing principal overseeing sales and operations of Windsor and NFP Life Solutions. Marc received his J.D. from American University Washington College of Law and is a former Finesca board member and past president of Forum400. LinkedIn
Mike Martini
President at Crump Life Insurance Services
Mike oversees the Crump and Hanleigh Insurance businesses, driving the evolution of both and delivering industry-leading results. He joined Crump in 2022 as executive vice president of business development and led the strategy that enabled the company to expand in the institutional space. As the President of Truist Life Insurance Services, he helped establish and grow the platform, which is now one of Crump’s largest sales channels. Mike has also held leadership roles at McGriff-California (a Truist Insurance Holdings sister company), a venture capital-backed firm, and in the information services industry. LinkedIn
Learn more about how the Galleri test can help your clients today
Only five out of 100+ known cancer types have recommended screening tests.1,2 Your clients deserve more. Introduce them to Galleri® – the first-of-its-kind multi-cancer early detection test that screens for some of the deadliest cancers before they become symptomatic, including pancreatic, ovarian, and liver.3*
The Galleri test does not detect a signal for all cancers and not all cancers can be detected in the blood. False positive and false negative results do occur. The Galleri test should be used in addition to healthcare provider recommended screening tests.
See Important Safety Information below.
* Sensitivity in study participants with - Pancreas cancer: 83.7% overall (61.9% stage I, 60.0% stage II, 85.7% stage III, 95.9% stage IV). Ovary cancer: 83.1% overall (50.0% stage I, 80.0% stage II, 87.1% stage III, 94.7% stage IV). Liver/bile duct cancer: 93.5% overall (100% stage I, 70.0% stage II, 100% stage III, 100% stage IV).
Have a question?
Use the form to submit a question to the committee.
The Galleri test is recommended for use in adults with an elevated risk for cancer, such as those aged 50 or older. The Galleri test does not detect all cancers and should be used in addition to routine cancer screening tests recommended by a healthcare provider. Galleri is intended to detect cancer signals and predict where in the body the cancer signal is located. Use of Galleri is not recommended in individuals who are pregnant, 21 years old or younger, or undergoing active cancer treatment.
Results should be interpreted by a healthcare provider in the context of medical history, clinical signs and symptoms. A test result of No Cancer Signal Detected does not rule out cancer. A test result of Cancer Signal Detected requires confirmatory diagnostic evaluation by medically established procedures (e.g. imaging) to confirm cancer.
If cancer is not confirmed with further testing, it could mean that cancer is not present or testing was insufficient to detect cancer, including due to the cancer being located in a different part of the body. False-positive (a cancer signal detected when cancer is not present) and false-negative (a cancer signal not detected when cancer is present) test results do occur. Rx only.
The GRAIL clinical laboratory is certified under the Clinical Laboratory Improvement Amendments of 1988 (CLIA) and accredited by the College of American Pathologists. The Galleri test was developed and its performance characteristics were determined by GRAIL. The Galleri test has not been cleared or approved by the Food and Drug Administration. The GRAIL clinical laboratory is regulated under CLIA to perform high-complexity testing. The Galleri test is intended for clinical purposes.
US Preventive Services Task Force. Recommended cancer screening tests, Grade A,B,C. Accessed 29April2024. https://www.uspreventiveservicestaskforce.org/uspstf/topic_search_results
NIH National Cancer Institute. Understanding cancer: What is cancer? https://www.cancer.gov/about-cancer/understanding/what-is-cancer
Klein EA, Richards D, Cohn A, et al. Clinical validation of a targeted methylation-based multi-cancer early detection test using an independent validation set. Ann Oncol. 2021;32(9):1167-77. DOI: https://doi.org/10.1016/j.annonc.2021.05.806